首页> 外文会议>Conference on advancing manufacture of cell and gene therapies >A NOVEL SCALABLE MANUFACTURING PLATFORM FOR T-CELL ACTIVATION AND EXPANSION IN ADOPTIVE T-CELL THERAPY
【24h】

A NOVEL SCALABLE MANUFACTURING PLATFORM FOR T-CELL ACTIVATION AND EXPANSION IN ADOPTIVE T-CELL THERAPY

机译:适应性T细胞治疗中T细胞活化和扩展的新型可扩展制造平台

获取原文

摘要

Adoptive T cell therapy (ACT) is growing rapidly, representing the revolution in cancer treatment. However, the current manufacturing platforms are largely based on magnetic microbeads surface coated with agonist antibodies to T-cell receptors CD3 and CD28. These manufacturing platforms use expensive reagents including the viral transduction vectors, and also require multiple discrete stages and open processes with significant human interaction, contributing to the high-cost for cGMP manufacturing of these therapies. We developed a single-use, beads-free bioreactor system (Figure 1a), which provides a closed-loop T-cell activation and expansion. The perfusion-based platform also facilitates the development of the bioreactor system into a fully automated, turn-key system used in both centralized and decentralized (e.g., hospitals) manufacturing settings. The bioreactor has a unique internal structure (Figure 1b), formed by a large number of interconnected hollow spheres tightly packed in a 3D space, which yields large surface areas to increase the reactivity between the bioreactor and the T cells flowing through the bioreactor. The surfaces of the bioreactor are coated with anti-CD3 and CD28 antibodies to mimic the antigens for T activation and expansion. The feasibility of using the perfusion-based bioreactor for T-cell activation and expansion is demonstrated in Figure 2. Briefly, 20×10~6 PBMCs were seeded into the bioreactor system and perfused for two days during the T-cell activation phase, with the medium containing no cytokine IL2. After two-day of activation, human IL-2 was added to the system so that the total IL-2 concentration was 20 IU/mL. Then the T-cell expansion phase wa carried out for three-days. On Day 5, T cells were achieved a three-time expansion after activation, which is similar to the magnetic beads-based system. However, the perfusion based bioreactor has the potential to offer multiple advantages over the current beads-based system as discussed above.
机译:过继性T细胞疗法(ACT)迅速发展,代表着癌症治疗的革命。然而,当前的制造平台主要基于表面涂有针对T细胞受体CD3和CD28的激动剂抗体的磁性微珠。这些制造平台使用昂贵的试剂,包括病毒转导载体,并且还需要多个离散的阶段和开放的过程,并且需要大量的人为干预,这为这些疗法的cGMP制造带来了高成本。我们开发了一种一次性的无珠生物反应器系统(图1a),该系统提供了一个闭环T细胞活化和扩增。基于灌注的平台还有助于将生物反应器系统开发为在集中式和分散式(例如医院)制造环境中使用的全自动,交钥匙系统。生物反应器具有独特的内部结构(图1b),该内部结构由紧密地堆积在3D空间中的大量相互连接的空心球形成,从而产生了较大的表面积,从而提高了生物反应器与流过生物反应器的T细胞之间的反应性。生物反应器的表面涂有抗CD3和CD28抗体,以模仿抗原的T活化和扩增作用。图2展示了使用基于灌注的生物反应器进行T细胞活化和扩增的可行性。简而言之,将20×10〜6个PBMC接种到生物反应器系统中,并在T细胞活化阶段进行两天的灌注,不含细胞因子IL2的培养基。激活两天后,将人IL-2添加到系统中,以使总IL-2浓度为20 IU / mL。然后,T细胞扩增阶段进行了三天。在第5天,激活后,T细胞实现了三倍扩增,这类似于基于磁珠的系统。但是,基于灌注的生物反应器具有比上述当前的基于珠子的系统提供多种优势的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号